Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naltrexone for Prolonged Grief Disorder
NCT06140420Phase 4Terminated
- Sponsor
- Texas Tech University
- Start
- Aug 2023
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in prolonged grief disorder (PGD) comparing Placebo with Naltrexone (2 arms). Primary endpoints: Prolonged Grief Disorder symptom severity at 12 weeks and Prolonged Grief Disorder severity at 8 weeks. Started Aug 2023; status: terminated.
02
Drugs
naltrexone
03
Conditions
prolonged grief disorder (PGD)
Beyond the preview
Go deeper on NCT06140420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06140420.